Sign in
Back to Risk Engine

Risk attribution — Jeanette Bailey

v1.0 · cal 2026-05-22

Component breakdown showing every feature that contributed to this patient's risk score.

Computed = stored(J vs J)Open patient detail

Computed score

100

Group J · Stage IV / progressing

Stored A–J score

94

Group J · Stage IV / progressing

Score buildup

Baseline 5 + +153 positive = 100

BaselineDemographicSymptomComorbidityImagingProcedurePathologyTreatmentResponse

Demographic

Subtotal +5

  • Age ≥ 70

    Advanced age is an independent risk factor for PDAC.

    Evidence: Current age 85· Threshold: 70 years

    +5

Symptom

Subtotal +26

  • Abdominal pain at age ≥ 50

    Unexplained abdominal pain in a patient over 50 warrants pancreas evaluation.

    Evidence: Onset 2023-02-19· Triggers PANDA group C

    +14

  • Weight loss at age ≥ 50

    Unintentional weight loss after 50 raises concern for occult malignancy.

    Evidence: Onset 2023-03-01

    +12

Comorbidity

Subtotal +13

  • Has chronic condition(s)

    Chronic disease burden warrants ongoing surveillance.

    Evidence: 4 active conditions

    +13

Imaging

Subtotal +10

  • CT of abdomen on record

    Imaging suggests the patient has been worked up for pancreatic concern.

    Evidence: CT on 2023-09-03

    +10

Procedure

Subtotal +42

  • EUS performed

    EUS is the highest-resolution modality for sub-cm pancreatic lesions; performance implies clinical concern.

    Evidence: Endoscopic ultrasonography of pancreas on 2023-06-21· Triggers PANDA group G

    +20

  • Tissue diagnosis procedure

    Biopsy or resection indicates definitive workup or treatment.

    Evidence: EUS-guided fine needle aspiration of pancreas on 2023-06-24

    +22

Pathology

Subtotal +25

  • Pancreatic tumor confirmed

    Confirmed pancreatic malignancy is the defining factor for groups H–J.

    Evidence: Malignant neoplasm of head of pancreas· Triggers PANDA group H

    +25

Treatment

Subtotal +20

  • Active chemotherapy

    Active cytotoxic therapy implies confirmed malignancy with treatment intent.

    Evidence: Gemcitabine 1000 MG/M2 Injection, Nab-paclitaxel 125 MG/M2 Injection· Triggers PANDA group I

    +20

Response

Subtotal +12

  • Patient deceased

    Score retained for cohort/historical analytics; treatment intent is post-mortem.

    Evidence: Death recorded 2000-08-05

    +12

The Risk Engine computed group (J) is derived purely from the feature contributions above. The stored A–J group (J) comes from the cascade classifier in scripts/classify-risk.ts. Divergence between the two indicates a classifier rule that the scoring weights haven't captured, or vice versa — useful for calibration.